CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy - 01/09/11
Abstract |
Despite cutaneous B-cell lymphoma often having a relatively indolent course and low mortality, it is often resistant to conventional therapy and frequently relapses. We describe a patient with widespread cutaneous B-cell lymphoma who was treated successfully with a recently approved chimeric monoclonal antibody directed against the CD20 antigen (rituximab) and the CD20-negative relapse that resulted. (J Am Acad Dermatol 2002;46:441-3.)
Le texte complet de cet article est disponible en PDF.Plan
Reprint requests: Elizabeth McBurney, MD, 1051 Gause Blvd, Suite 460, Slidell, LA 70459-2179. |
Vol 46 - N° 3
P. 441-443 - mars 2002 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?